Are SSRIs Doing More Harm Than Good? | Shawn Wells

Name: Are SSRIs Doing More Harm Than Good? | Shawn Wells
Uploaded: 2024-10-09T12:00:17+00:00
Duration: 53 s
Channel: Claudia von Boeselager
Description: In this segment, the presenter highlights two high‑profile meta‑analyses (2017 and 2022) that suggest selective serotonin reuptake inhibitors (SSRIs) may…

9 Oct 2024 · 1 min

Watch on YouTube

0:53

In this segment, the presenter highlights two high‑profile meta‑analyses (2017 and 2022) that suggest selective serotonin reuptake inhibitors (SSRIs) may cause more harm than benefit, with results deemed inconclusive at best. He notes that SSRI prescriptions have risen by about 25% since the COVID‑19 pandemic, implying that side‑effects now outweigh therapeutic gains for a condition—depression—that he describes as a pandemic itself. The speaker then contrasts this with emerging research over the past 8–10 years on psychedelic‑based treatments (MDMA, psilocybin, ketamine), which report cure or response rates ranging from 50% to 80%, positioning psychedelics as potentially more effective alternatives for depression.

Chapters

There is two meta-analyses on SSRIs, uh, 2017, 2022, in some of the most prestigious journals. And, and in those two meta-analyses, they found that they potentially did more harm than good, and the results were at best inconclusive. Um, so those drugs are widely prescribed and up 25% in terms of prescription since COVID happened. And so the side effects, as they were saying, were greater than the benefit. And think about that, and that's what we're using as our major number one go-to tool for depression. And depression is pandemic. It is pandemic. If we look at the studies that have been done over the last maybe 8 to 10 years on psychedelics, where we look at MDMA, we look at psilocybin, we look at ketamine potentially, we are seeing 50 to 80% cure rates.